Renal Dynamics (ReDy) exhibited pre-clinical results at the Cardiovascular Research Technologies 2015 meeting. Safety and efficacy results on ReDy’s third-generation renal denervation system used on a porcine model study were presented. The system’s non-occluding blood isolation membrane allows for deep delivery of RF power into the tissue at relatively low treatment powers. Additionally, the low-profile catheter offers a means of treating challenging anatomy with a single device.
The study results were presented by Rami Tzafriri, PhD, Principal Scientist, CBSET. “CBSET’s expertise in biomarker assays and histopathology methods, combined with computational bioheat models, has highlighted the sensitivity of renal denervation effects to tissue microanatomy and innervation patterns, providing a framework by which to optimize treatment efficacy and safety,” Dr. Tzafriri explained.
“We’re proud to have employed our scientific expertise and unique models to help Renal Dynamics advance important and novel design elements into their third-generation renal denervation technology. Focusing on the current clinical challenges, our combined efforts have generated data that has further advanced the field while minimizing animal usage and overall program costs,” said Peter Markham, President, CEO, CBSET.
ReDy’s CEO and President, Mr. Shawn Moaddeb, said, “These results are extremely exciting, since they indicate that the ReDy system can deliver low power and create consistent lesion formation using a single universal catheter. We are confident that the ReDy System will increase renal denervation efficacy and patient comfort during the procedure.”
Hypertension is a chronic medical condition in which blood pressure in the arteries is elevated. Blood pressure is expressed by two measurements, systolic and diastolic pressures, which are the maximum and minimum pressures, respectively, in the arterial system. Normal blood pressure at rest is within the range of 100-140 mmHg systolic and 60-90 mmHg diastolic. Hypertension is present if the blood pressure is persistently at or above 140/90 mmHg for adults. Sustained hypertension over time is a major risk factor for heart disease, coronary artery disease, stroke, aortic aneurysm, peripheral artery disease and chronic kidney disease. Hypertension affects over 1 billion people worldwide.
About renal denervation
Renal denervation is an interventional approach for the treatment of high blood pressure. A minimally-invasive, endovascular-catheter-based procedure, it uses radiofrequency or ultrasound ablation to treat resistant hypertension. Nerves in the wall of the renal artery are ablated through the application of radiofrequency pulses to the renal arteries. This causes reduction of sympathetic activity in the kidney, resulting in a clinically-relevant decrease in blood pressure.
About Renal Dynamics
Renal Dynamics (ReDy), a member of the Hobart Group of companies, is dedicated to treating hypertension with a single intervention, using its proprietary Renal Denervation System. ReDy is focused on developing a solution that is easy and quick to administer, uses one universal catheter and provides increased patient comfort. For more information, visit Renal-Dynamics.com.
About Hobart Group
The Hobart Group develops and commercializes medical technologies, targeting top healthcare markets with significant unmet needs. Its growing portfolio of companies covers the areas of cardiology, diabetes, oncology, neurology and rehabilitation. Together, Hobart Group companies have over 200 scientists, engineers, regulatory and business experts across four continents, benefitting from clinical expertise and extensive regulatory and international market knowledge across Europe, the USA and Asia. For more information, visit www.Hobart-Group.com.
For media enquiries
Mrs. Sharon Alon
Tel: +1 347-566-6113